Esperion Therapeutics Inc logo

ESPR

Materials

Esperion Therapeutics Inc

$3.15+0.03 (+0.96%)PRE

Live · NASDAQ · May 9, Close

AI Insight

What's Moving ESPR Today?

No stock-specific AI insight has been generated for ESPR yet. Check back soon — insights are generated from recent news analysis.

Fundamentals

Market Cap$811M
P/E Ratio
EPS
Dividend Yield
Dividend / Share
ROE
Profit Margin
Debt / Equity

Trading

Volume23.8M
Avg Volume (10D)
Shares Outstanding257.4M

ESPR News

20 articles

All 20 articles loaded

Price Data

Open$3.11
Previous Close$3.12
Day High$3.12
Day Low$3.10
52 Week High
52 Week Low

About Esperion Therapeutics Inc

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

294 employees
Listed June 26, 2013
MaterialsPHARMACEUTICAL PREPARATIONS

Company Details

Security TypeStock
ExchangeNASDAQ
Currency
Round Lot
SICPHARMACEUTICAL PREPARATIONS
CIK
Composite FIGI
Share Class FIGI